UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of July 2025
Commission File Number: 001-42484
ASCENTAGE PHARMA GROUP INTERNATIONAL
(Translation of Registrant’s name into
English)
68 Xinqing Road
Suzhou Industrial Park
Suzhou, Jiangsu
China
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
On July 25, 2025, Ascentage
Pharma Group International issued an announcement entitled, “Closing of Placing of Existing Shares and Top-Up Subscription of New
Shares Under General Mandate”. A copy of the announcement is furnished as Exhibit 99.1 to this Report.
INDEX TO EXHIBITS
Exhibit
Number |
|
Exhibit Title |
99.1 |
|
Announcement dated July 25, 2025
|
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
ASCENTAGE PHARMA GROUP INTERNATIONAL |
|
|
|
Date: July 25, 2025 |
/s/ Dajun Yang |
|
Name: |
Dajun Yang |
|
Title: |
Chief Executive Officer |